{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rotavirus+vaccine",
    "query": {
      "intervention": "Rotavirus vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rotavirus+vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T11:43:45.663Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02096263",
      "title": "Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Poliomyelitis",
        "Diphtheria",
        "Haemophilus Influenzae Type b",
        "Tetanus",
        "Acellular Pertussis",
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Infanrix hexa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ActHIB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pentacel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Infanrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiberix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 585,
      "start_date": "2014-04-16",
      "completion_date": "2015-11-13",
      "has_results": true,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-09-08T11:43:45.663Z",
      "location_count": 43,
      "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096263"
    },
    {
      "nct_id": "NCT06962904",
      "title": "CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rotavirus Infections"
      ],
      "interventions": [
        {
          "name": "3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 50,
      "start_date": "2025-07-07",
      "completion_date": "2026-10-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-09-08T11:43:45.663Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06962904"
    },
    {
      "nct_id": "NCT01978093",
      "title": "Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neisseria Meningitidis",
        "Haemophilus Influenzae Type b"
      ],
      "interventions": [
        {
          "name": "Hib-MenCY-TT (MenHibrix®)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PedvaxHIB®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 600,
      "start_date": "2014-02-01",
      "completion_date": "2016-03-18",
      "has_results": true,
      "last_update_posted_date": "2018-09-14",
      "last_synced_at": "2026-09-08T11:43:45.663Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01978093"
    },
    {
      "nct_id": "NCT01266850",
      "title": "Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rotavirus Infection"
      ],
      "interventions": [
        {
          "name": "Rotarix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RotaTeq®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "14 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 14 Weeks"
      },
      "enrollment_count": 1384,
      "start_date": "2011-03",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2014-10-28",
      "last_synced_at": "2026-09-08T11:43:45.663Z",
      "location_count": 13,
      "location_summary": "Oakland, California • Atlanta, Georgia • Iowa City, Iowa + 8 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01266850"
    },
    {
      "nct_id": "NCT00806195",
      "title": "Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis",
        "Meningococcal Infection"
      ],
      "interventions": [
        {
          "name": "MenACWY-CRM197",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP (Diptheria, Tetanus, Pertussis) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hib (Haemophilus influenza b) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IPV (Inactivated Polio Vaccine) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR (Measles, Mumps, and Rubella) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A Virus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "55 Days to 89 Days"
      },
      "enrollment_count": 7744,
      "start_date": "2008-12",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2013-07-09",
      "last_synced_at": "2026-09-08T11:43:45.663Z",
      "location_count": 130,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00806195"
    },
    {
      "nct_id": "NCT01049035",
      "title": "A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meningitis",
        "Meningococcal Infection"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella Virus Vaccine Live",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "365 Days",
        "sex": "ALL",
        "summary": "42 Days to 365 Days"
      },
      "enrollment_count": 580,
      "start_date": "2009-12-16",
      "completion_date": "2012-02-13",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-09-08T11:43:45.663Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01049035"
    },
    {
      "nct_id": "NCT06824181",
      "title": "Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Immunization"
      ],
      "interventions": [
        {
          "name": "PCV21 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 20 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RotaTeq",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaxelis vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Priorix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VAQTA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "42 Days to 89 Days"
      },
      "enrollment_count": 580,
      "start_date": "2025-02-27",
      "completion_date": "2027-09-10",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-09-08T11:43:45.663Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Hollywood, Florida • Miami, Florida + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06824181"
    },
    {
      "nct_id": "NCT02542462",
      "title": "Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intussusception",
        "Rotavirus Infections"
      ],
      "interventions": [
        {
          "name": "Rotarix®,",
          "type": "DRUG"
        },
        {
          "name": "Rotarix®, with other routine vaccines",
          "type": "DRUG"
        },
        {
          "name": "RotaTeq®,",
          "type": "DRUG"
        },
        {
          "name": "RotaTeq®, with other routine vaccines",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "90 Days",
        "sex": "ALL",
        "summary": "42 Days to 90 Days"
      },
      "enrollment_count": 144,
      "start_date": "2015-11",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2018-07-12",
      "last_synced_at": "2026-09-08T11:43:45.663Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02542462"
    },
    {
      "nct_id": "NCT03207750",
      "title": "This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rotavirus Infection",
        "Rotavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiberix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevenar 13",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 1280,
      "start_date": "2017-09-14",
      "completion_date": "2019-03-01",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-09-08T11:43:45.663Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207750"
    },
    {
      "nct_id": "NCT03621670",
      "title": "Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiberix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline water)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 20",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 1196,
      "start_date": "2018-07-27",
      "completion_date": "2024-12-27",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-08T11:43:45.663Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03621670"
    }
  ]
}